Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 23,021 shares, a drop of 51.0% from the June 30th total of 46,964 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 97,056 shares, the days-to-cover ratio is currently 0.2 days.
Straumann Stock Performance
Shares of SAUHY opened at $11.76 on Tuesday. Straumann has a 12 month low of $9.44 and a 12 month high of $13.73. The company has a 50-day moving average price of $12.28 and a two-hundred day moving average price of $11.68.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on SAUHY. Barclays restated an “overweight” rating on shares of Straumann in a research note on Thursday, June 18th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Straumann in a research note on Tuesday, June 30th. Morgan Stanley reissued an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. BMO Capital Markets began coverage on shares of Straumann in a research report on Wednesday, July 8th. They issued an “outperform” rating on the stock. Finally, Citigroup restated a “sell” rating on shares of Straumann in a report on Thursday, July 9th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold”.
About Straumann
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
See Also
- Five stocks we like better than Straumann
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
